Prasco LLC   Report issue

For profit Phase 3
Founded: Mason OH United States (2002)
Status: No NME R&D (2002)

Organization Overview

First Clinical Trial
2017
NCT03332303
First Marketed Drug
2002
dexamethasone
First NDA Approval
None
Last Known Activity
2017

Timeline

NOW
  • Now

Alternative names

PRASCO | PRASCO LABS LLC | Prasco LLC

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Atrophy (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 1
  • # of Trial APIs: 1